Last reviewed · How we verify

Krankenhaus Barmherzige Schwestern Linz — Portfolio Competitive Intelligence Brief

Krankenhaus Barmherzige Schwestern Linz pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Xylocaine 10% pump spray Xylocaine 10% pump spray marketed
Saline solution isotonic 0.9% NaCl Saline solution isotonic 0.9% NaCl marketed Crystalloid fluid / Electrolyte replacement solution General supportive care / Fluid and electrolyte management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Dr. Waseem Ullah · 1 shared drug class
  2. Fayoum University Hospital · 1 shared drug class
  3. GCP-Service International West GmbH · 1 shared drug class
  4. Hospital Central "Dr. Ignacio Morones Prieto" · 1 shared drug class
  5. Hospital Italiano de Buenos Aires · 1 shared drug class
  6. Hvidovre University Hospital · 1 shared drug class
  7. Hédi Chaker Hospital · 1 shared drug class
  8. Kecioren Education and Training Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Krankenhaus Barmherzige Schwestern Linz:

Cite this brief

Drug Landscape (2026). Krankenhaus Barmherzige Schwestern Linz — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/krankenhaus-barmherzige-schwestern-linz. Accessed 2026-05-17.

Related